Aortic tissue sections or cell slides were incubated with primary antibodies (1:200) against RAGE, p-NF-κB, TNF-α, IL-10, CD31, VEGF, LC3B, Beclin1, and P62 at 4°C for 1 h. Subsequently, the sections ...

BioN­Tech has high­ly en­cour­ag­ing sur­vival da­ta for its bis­pe­cif­ic an­ti­body com­bin­ing check­point block­ade with VEGF-A in­hi­bi­tion as a first-line treat­ment for ...

The quantification of the immunofluorescence intensity is shown as the mean and standard deviation (SD) of 23–29 individual images showing 112–154 Purkinje neurons. *p < 0.05 unpaired Student ...

To investigate whether angiogenic changes were related to vascular endothelial growth factor (VEGF), senescent cells and controls were lysed, and VEGF was quantified using RT-qPCR. Secretory VEGF ...

CAMSAP2 is dynamically localized at the Golgi during the reorientation process in directional cell migration. (A) Immunofluorescence staining of HT1080 located at the foremost edge of the cell wound ...

Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET "The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can ...

Epicrispr Biotechnologies has raised $68 million in pursuit of a first-of-its-kind genetic medicine for a rare neuromuscular disorder called facioscapulohumeral muscular dystrophy. EPI-321, the ...

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data ...

Behind SZN-413 are four other preclinical eye drugs targeting Fzd4, Fzd127 or VEGF. Today’s decision is Surrozen’s latest move to streamline its pipeline, having jettisoned a clinical-stage ...

We look forward to advancing UBX1325 to late-stage studies against aflibercept in DME patients with inadequate response to anti-VEGF therapies.” Of the 1.7 million people in the U.S. with DME ...

Atea had been evaluating a 2-mg dose of sozinibercept every four or eight weeks in combination with Regeneron’s blockbuster VEGF inhibitor Eylea in patients with wet age-related macular ...